Intract Pharma is pioneering oral biologics delivery by converting complex injectable biologic medicines into orals for chronic indications using its proprietary Soteria™ and Phloral™ delivery platforms. Our unique approach involves targeting large biologic drugs such as monoclonal antibodies directly to the ileum/colon, stabilise them against microbiome derived enzymes and enhance it’s local tissue and/or systemic exposure. Our first goal is to advance our lead oral antibody therapeutic that can provide a safer and more effective oral option for patients suffering from chronic inflammatory bowel diseases representing >$7bn market opportunity.